LigaChem Biosciences Inc.

KOSDAQ:A141080 Stock Report

Market Cap: ₩3.5t

LigaChem Biosciences Future Growth

Future criteria checks 5/6

LigaChem Biosciences is forecast to grow earnings and revenue by 98.8% and 28.3% per annum respectively. EPS is expected to grow by 95% per annum. Return on equity is forecast to be 5.5% in 3 years.

Key information

98.8%

Earnings growth rate

95.0%

EPS growth rate

Life Sciences earnings growth27.0%
Revenue growth rate28.3%
Future return on equity5.5%
Analyst coverage

Low

Last updated02 Dec 2024

Recent future growth updates

Recent updates

Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%

Nov 29
Risks Still Elevated At These Prices As LigaChem Biosciences Inc. (KOSDAQ:141080) Shares Dive 26%

LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 09
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money

May 23
Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money

A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

Mar 29
A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?

Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

Dec 07
Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)

Earnings and Revenue Growth Forecasts

KOSDAQ:A141080 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026235,46853,50082,96758,6005
12/31/2025249,17160,00085,13354,8755
12/31/2024162,262-5,000-9,60017,2005
9/30/2024101,417-2,93243,37546,717N/A
6/30/202476,216-33,94754,77956,831N/A
3/31/202457,543-46,54361,22363,270N/A
12/31/202334,146-73,704-64,438-62,236N/A
9/30/202334,470-83,053-51,935-50,483N/A
6/30/202335,643-71,784-31,067-29,782N/A
3/31/202335,266-54,336-31,871-28,402N/A
12/31/202233,412-45,092-11,908-7,136N/A
9/30/202241,783-5,173-23,071-13,416N/A
6/30/202239,789-5,443-47,026-29,862N/A
12/31/202132,157-23,391-60,493-42,049N/A
12/31/201957,50013,58620,62624,113N/A
9/30/201951,280-1,07311,84415,351N/A
6/30/201929,947-24,220-14,347-11,102N/A
3/31/201928,452-23,197-15,196-12,802N/A
12/31/201825,240-25,770-16,728-12,758N/A
9/30/201824,869-15,221-18,020-14,049N/A
6/30/201823,907-10,598N/A-301N/A
3/31/201823,177-12,034N/A-7,192N/A
12/31/201722,057-12,934N/A-8,213N/A
9/30/201720,790-15,746N/A-7,222N/A
6/30/201718,845-15,890N/A-18,216N/A
3/31/201717,541-16,183N/A-11,895N/A
12/31/201616,655-14,725N/A-13,039N/A
9/30/201613,720-8,330N/A-10,609N/A
6/30/201610,294-8,192N/A-9,457N/A
3/31/20166,295-7,671N/A-9,535N/A
12/31/20151,788-8,237N/A-8,780N/A
12/31/2014870-8,686N/A-7,882N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A141080 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: A141080 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A141080 is expected to become profitable in the next 3 years.

Revenue vs Market: A141080's revenue (28.3% per year) is forecast to grow faster than the KR market (8.9% per year).

High Growth Revenue: A141080's revenue (28.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A141080's Return on Equity is forecast to be low in 3 years time (5.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 16:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LigaChem Biosciences Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mujinn LeeCape Investment & Securities Co., Ltd.
Seohyun LeeCitigroup Inc
Jisoo LeeDAOL Investment & Securities Co., Ltd.